New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
05:35 EDTNSRGY, VRX, LRLCYNestle creates Nestle Skin Health with acquisition of Valeant assets for $1.4B
Nestlé (NSRGY) announced it would extend its activities to include the field of specialized medical skin treatments through the creation of Nestlé Skin Health S.A. The foundation for the company would be Galderma, the 50/50 joint venture with L'Oreal (LRLCY), which would become fully-owned by Nestlé. Bübchen, the company's existing infant skin care business would be merged into the new entity. The acquisition of Galderma is awaiting final regulatory clearance. Nestlé is announcing it will reinforce Nestlé Skin Health with the acquisition from the Canadian firm Valeant Pharmaceuticals (VRX) of the full rights to commercialize several key aesthetic dermatology products in the U.S. and Canada for $1.4B in cash. The two markets together represent more than half of the fast-growing medical aesthetics market around the world. Galderma already commercializes the products included in this transaction outside those markets. Nestlé is acquiring the full rights to commercialize in the U.S. and Canada Restylane, Perlane and Emervel, products used for corrective facial aesthetic treatments, and Dysport, an aesthetic dermatology treatment. It will also acquire the full rights to Sculptra, a unique treatment for aesthetic and medical uses in the U.S., Canada and many markets around the world.
News For NSRGY;VRX;LRLCY From The Last 14 Days
Check below for free stories on NSRGY;VRX;LRLCY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
05:37 EDTVRXValeant, Pershing Square, Allergan settle pending litigation before DE Court
Subscribe for More Information
September 12, 2014
08:02 EDTVRXPershing submits special meeting requests totaling 35% of Allergan shares
Subscribe for More Information
05:09 EDTVRXAllergan comments on Pershing Square delivery of additional requests
Allergan (AGN) commented on Pershing Square Capital Management delivery of additional requests from stockholders owning 1.5% of Allergan’s shares to call a Special Meeting of Stockholders. Allergan will review these requests in addition to the requests from stockholders owning 2.8% of Allergan’s shares that were delivered on September 3. The company issued the following statement: Notwithstanding Pershing Square and Valeant Pharmaceuticals (VRX) efforts to change the subject, Allergan recognizes that what actually matters is value, and that’s what the company is focusing on delivering to stockholders. In that regard, Allergan’s current strategic plan is expected to deliver a compounded annual growth rate of greater than 20% EPS growth, including estimated 2016 EPS at approximately $10.00. Allergan has already scheduled the Special Meeting for December 18. As such, the delivery of additional requests for the Special Meeting by Pershing Square is not a meaningful development. The lawsuit in California is seeking an order barring Valeant, Pershing Square, Ackman, and entities affiliated with them from voting shares that Allergan believes were acquired in violation of the federal securities laws, including insider trading. If Allergan’s motion for a preliminary injunction is granted, it would prevent Valeant, Pershing Square, and Ackman from voting their shares at any meeting of stockholders.
September 11, 2014
09:52 EDTVRXValeant to submit consent from 35% of Allergan holders, CNBC reports
Subscribe for More Information
September 9, 2014
10:10 EDTLRLCYOn the Fly: Analyst Downgrade Summary
Subscribe for More Information
07:53 EDTLRLCYL'Oreal downgraded to Outperform from Strong Buy at Raymond James
06:42 EDTVRXLew expects to make decision on combating inversion deals soon, NY Times reports
Subscribe for More Information
05:42 EDTLRLCYL'Oreal downgraded to Outperform from Strong Buy at Raymond James
Raymond James downgraded L'Oreal to Outperform and removed the stock from its European Conviction List citing the CEO's cautious message on cosmetics market momentum in the second half of 2014.
September 8, 2014
17:01 EDTVRXValeant to expand Bausch + Lomb facility, will add 120 new jobs
Valeant Pharmaceuticals announced that the company hosted a ribbon cutting ceremony for the new Bausch + Lomb ULTRA contact lens manufacturing lines and solar array assembly at the company's Optics Center in Rochester, NY. The ceremony recognized the expansion and installation of the new manufacturing lines, which will produce the company's silicone hydrogel contact lens, Bausch + Lomb ULTRA. The solar array, which is currently under construction, will generate and supply electricity through the installation of 3,667 solar panels, helping to reduce the Rochester facility's carbon footprint by 800 tons of carbon dioxide emissions annually.
September 5, 2014
10:05 EDTVRXOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) initiated with a Buy at ISI Group... Akamai (AKAM) initiated with a Buy at UBS... Alexion (ALXN) initiated with a Buy at SunTrust... Allegion (ALLE) initiated with a Buy at Buckingham... Allergan (AGN) initiated with a Buy at ISI Group... Aviat Networks (AVNW) initiated with a Neutral at H.C. Wainwright... Celgene (CELG) initiated with a Buy at SunTrust... EZCORP (EZPW) initiated with a Hold at Jefferies... Eaton (ETN) initiated with a Neutral at Buckingham... Emerson (EMR) initiated with a Neutral at Buckingham... HMS Holdings (HMSY) initiated with an Overweight at Stephens... Incyte (INCY) initiated with a Buy at SunTrust... Ingersoll-Rand (IR) initiated with a Neutral at Buckingham... Insmed (INSM) initiated with an Outperform at Cowen... Intercept (ICPT) initiated with an Outperform at Cowen... Johnson & Johnson (JNJ) initiated with an Outperform at BMO Capital... Lennox (LII) initiated with a Neutral at Buckingham... Mylan (MYL) initiated with a Hold at ISI Group... Orion Engineered Carbons (OEC) initiated with a Buy at Goldman... Parker-Hannifin (PH) initiated with a Buy at Buckingham... Pentair (PNR) initiated with a Neutral at Buckingham... Pharmacyclics (PCYC) initiated with a Neutral at SunTrust... Rockwell Automation (ROK) initiated with a Neutral at Buckingham... Sabre (SABR) initiated with an Outperform at Oppenheimer... Santander Consumer (SC) initiated with a Buy at Jefferies... Springleaf (LEAF) initiated with a Buy at Jefferies... Susser Petroleum (SUSP) initiated with a Neutral at Credit Suisse... Teva (TEVA) initiated with a Buy at ISI Group... Valeant (VRX) initiated with a Buy at ISI Group... WESCO (WCC) initiated with a Neutral at Buckingham... Watsco (WSO) initiated with a Neutral at Buckingham... Weyerhaeuser (WY) initiated with a Neutral at JPMorgan... World Acceptance (WRLD) initiated with a Hold at Jefferies.
September 4, 2014
17:16 EDTVRXValeant initiated with a Buy at ISI Group
Target $159.
09:44 EDTVRXValeant, Ackman deliver another 2.8% consent vote to Allergan, CNBC reports
Valeant (VRX) and Bill Ackman delivered another 2.8% consent vote to Allergan, bringing its total vote to call a special meeting to 33.8%, CNBC's David Faber reports, citing sources. A special meeting has been set for December 18, Faber added.
September 2, 2014
09:07 EDTVRXAllergan filed answer in federal court reponding to Valeant, Pershing claims
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use